Cover of: Filgrastim (r-metHuG-CSF) in Clinical Practice | George Morstyn Read Online

Filgrastim (r-metHuG-CSF) in Clinical Practice

  • 471 Want to read
  • ·
  • 10 Currently reading

Published by Informa Healthcare .
Written in English


  • Specific disorders & therapies,
  • Therapeutic use,
  • Cancer Chemotherapy,
  • Medical / Nursing,
  • Medical,
  • Filgrastim,
  • Medical / Internal Medicine,
  • Oncology,
  • Pharmacology

Book details:

Edition Notes

Second Edition

The Physical Object
Number of Pages673
ID Numbers
Open LibraryOL8124440M
ISBN 100824700570
ISBN 109780824700577

Download Filgrastim (r-metHuG-CSF) in Clinical Practice


A glycoprotein, filgrastim binds to and stimulates immature neutrophils to divide and differentiate. Also activates mature neutrophils. Therapeutic Effects: Decreased incidence of infection in patients who are neutropenic from chemotherapy or other causes. Improved harvest of progenitor cells for bone marrow transplantation. + +. Name /bks__deglins_md_disk/filgrastim 02/12/ PM Plate # 0-Composite pg 1 # 1 PDF Page #1 Canadian drug name. Genetic Size: KB.   In Summary. Commonly reported side effects of filgrastim include: hyperuricemia, increased lactate dehydrogenase, increased leukocyte alkaline phosphatase, increased serum alkaline phosphatase, ostealgia, and side effects include: arthralgia, headache, myalgia, and pruritus. See below for a comprehensive list of adverse effects.9/ Providing a wealth of insights drawn from the experience of groundbreaking researchers working in the field, this Second Edition of a landmark volume brings preclinical and clinical studies of Filgrastim (r-metHuG-CSF) up to date with completely revised and expanded discussions of its biology, biochemistry, structure, pharmacology, clinical applications, and by:

filgrastim is a topic covered in the Davis's Drug Guide.. To view the entire topic, please sign in or purchase a subscription.. Nursing Central is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,+ drugs or refer to 65,+ dictionary terms. FILGRASTIM: MCG/ML: SYRINGE: Prescription: None No: No: Approval Date(s) and History, Letters, Labels, Reviews for BLA Original Approvals or Tentative Approvals. Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url;. Pegfilgrastim has a longer half-life than filgrastim, particularly after the administration of chemotherapy. Because pegfilgrastim is cleared by neutrophils and their precursors, its half-life is prolonged by chemotherapy, and in this setting the drug is “self-regulating,” with levels persisting through the postchemotherapy nadir and.   Filgrastim in Clinical Practice by George Morstyn, T. Michael Dexter, MaryAnn Foote | Editorial Reviews. Filgrastim as treatment or prophylaxis for decreasing infectious episodes, intensifying immunosuppresive therapy, and mobilizing progenitor stem cells In this second edition of the book, each chapter has been revised and Author: George Morstyn.

Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url; 08/01/ SUPPL Labeling-Package Insert. FDA approves Neupogen for treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident. On Ma , FDA approved use of . Proper Use. Drug information provided by: IBM Micromedex A nurse or other trained health professional may give you this medicine. It is given as a shot under your skin or into a vein. Purple Book: Database of Licensed Biological Products. Advanced Search. Enter data into one or more fields below. Click the View All Database Entries to view all products in the database. Purple Book database last updated on: March 9th, Search. Reset. Additional Search Filters.